• Xeris Biopharma granted director Menassie Taddese 22,365 common shares on November 2, 2026.
• Taddese also received 31,499 stock options with a $10.17 exercise price, expiring November 2, 2036.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001867096-26-000105), on November 04, 2026, and is solely responsible for the information contained therein.